Ropanicant
Small moleculeexperimental
Clinical trial activity
4 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started May 22, 2017 (NCT03155503)
Timeline
Indications
Mechanism of action
Chemistry & pharmacology
Loading structure…
SMILES
Clc1ccc(OC[C@@H]2C[C@H]3C[C@H]3N2)cn1- Mol. weight
- 224.69 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- Yes
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4650579 ↗
Also known as
- suvn-911
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06836063 | Phase 2 | Apr 30, 2025 | Suven Life Sciences Limited |
| NCT06126497 | Phase 2 | Jan 31, 2024 | Suven Life Sciences Limited |
| NCT03551288 | Phase 1 | May 22, 2018 | IQVIA, Suven Life Sciences Limited |
| NCT03155503 | Phase 1 | May 22, 2017 | IQVIA, Suven Life Sciences Limited |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Suven Life Sciences Limited | For profit | 4 | 4 | 2 | 2017 |
| IQVIA | For profit | 2 | 0 | 1 | 2017 |
2 organizations
Page 1 / 1